Analysis of Intragroup Preferences of Patients of Far Eastern Federal District in Purchase of Antihypertensive Preparations

Arterial hypertension is one of the most common chronic diseases. Regular blood pressure control to reach the target level is considered as the main way to reduce the risk of developing cardiovascular complications. Therapeutic classes, which are used as first-line drugs include calcium channel blockers (CCB), β-blockers, diuretics, angiotensin II receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors. The aim of the study is to analyze the intra-group preferences of the patients of the Far Eastern Federal District (FSD) when purchasing the five main classes of antihypertensive drugs. Materials and methods: DDD-analysis (162 pharmacy organizations), marketing analysis (share of realization), and statistical analysis (criteria of Kruskal-Wallis, and Spearman) were carried out. Results: The most acquired antihypertensive drugs in the therapeutic class of β-blockers is bisoprolol; among CCB is amlodipine; among the group of diuretics is indapamide; in the ARBs class are losartan and valsartan; and among the ACE inhibitors are enalapril and lisinopril. There are no statistically reliable differences in the structure of the purchase of drugs between the subjects of the FSD. Conclusion: The obtained data prove the unity of the approaches in carrying out drug therapy of arterial hypertension in ten subjects of FSD, and accordingly the full introduction of the guideline into functioning regional health systems. Scientific contribution: Research planning, DDD analysis, marketing analysis, statistical analysis, interpretation and generalization of the obtained data were carried out by the authors. Field of application: The results of this study can be used to assess the compliance of medical care with the current standards, as well as to plan the procurement of antihypertensive drugs for state and municipal needs to optimize the assortment matrix in pharmacy organizations. Future research may conduct a comparative analysis of the structure of antihypertensive drugs acquisition by patients of densely populated western and central regions with the subjects of the FSD.

1. Incidence of the population in the Russian Federation 2017. Statistical materials. Part II. Ministry of health of the Russian Federation. Department of health monitoring, analysis and strategic development of FSBU "Central research institute of health organization and informatization" of the Ministry of health of Russia. Moscow, 2018. - P. 90-9 URL: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god (Date of asses 02/11/2019).
2. Chazova, Y.V. Zhernakov on behalf of experts Clinical Guidelines. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019; 16(1):6-31. doi: 10.26442/2075082X.2019.1.190179.
3. Brunstrom M. Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA. 2018; 178: 28–36.
4. Ettehad D. Emdin C.A., Kiran A., Anderson S.G. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 5; 387(10022):957-967. doi:  10.1016/S0140-6736(15)01225-8.
5. Slivnick, J., Lampert B.C.  Hypertension and heart failure. Heart Fail Clin. 2019; 15(4):531-541. doi:  10.1016/j.hfc.2019.06.007.
6. Grassi G., Calhoun D.A., Mancia G., Carey R.M. Resistant hypertension management: comparison of the 2017 American and 2018 European high blood pressure guidelines. Curr Hypertens Rep.  2019; 21(9):67. doi: 10.1007/s11906-019-0974-3.
7. Hannah-Shmouni F., Gubbi S., Spence J.D., Stratakis C.A. et al Resistant hypertension: a clinical perspective. Endocrinol Metab Clin North Am. 2019; 48(4):811-828. doi:10.1016/j.ecl.2019.08.010.
8. Banga S., Mungee S., Patel A.R., Singh S. et al Management of resistant hypertension based on recommendations from different guidelines and the systolic blood pressure intervention trial. Cureus. 2019; 11(8):5371. doi: 10.7759/cureus.5371.
9. Nardin C., Rattazzi M., Pauletto P.  Blood pressure variability and therapeutic implications in hypertension and cardiovascular diseases. High Blood Press. Cardiovasc Prev. 2019: Sep 26. doi:10.1007/s40292-019-00339-z.
10. James P.A., Oparil S., Carter B.L. et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth joint national committee (JNC 8). J. Am. Med. Assoc. 2014; 311(5):507-520 doi: 1001/jama.2013.284427.
11. Mancia G. Fagard R., Narkiewicz K., Redón J.et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
12. Flack J.M., Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2019; May 15:S1050-1738(19)30068-4. doi:: 10.1016/j.tcm.2019.05.003.
13. Bundy J.D., Mills K.T., He J. Comparison of the 2017 ACC/AHA hypertension Guideline with earlier guidelines on estimated reductions in cardiovascular disease. Curr Hypertens Rep. 2019; 21(10):76. doi: 10.1007/s11906-019-0980-5.
14. Bakris G. Ali W., Parati G. ACC/AHA versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019; 73(23):3018-3026. doi:  10.1016/j.jacc.2019.03.507.
15. Vázquez-Narváez K.G. Ulibarri-Vidales M. The patient with hypertension and new guidelines for therapy. Curr Opin Anaesthesiol.  2019; 32(3):421-426. doi: 10.1097/ACO.0000000000000736.
16. Larina V.N., Bart B.J., Vartanyan E.A., Fedorov E.V., et al. Approaches to diagnosis and therapeutic tactics of arterial hypertension in light of European recommendations. Cardiology. 2019; 59(9):67-70. https://doi.org/10.18087/cardio.2019.9.n518.
17. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015; 33(7):1321–41. doi:  10.1097/HJH.0000000000000614.
18. Suchard M.A., Schuemie M.J., Krumholz H.M.., You S.C. et al Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019: Oct 24:S0140-6736(19)32317-7. doi:   10.1016/S0140-6736(19)32317-7.
19. Campbell N.R.C. A step in the global effort to control hypertension: Fixed dose combination antihypertensive drugs.J Clin Hypertens (Greenwich). 2019; 21(9):1426-1428. doi:   10.1111/jch.13683.
20. Polychronopoulou E., Burnier M., Wuerzner G. Hypertension in the elderly: have new guidelines changed the management? Rev Med Suisse. 2019; 15(662):1597-1602.
21. Lee J.H., Kim K.I., Cho M.C. Current status and therapeutic considerations of hypertension in the elderly. Korean J Intern Med. 2019; 34(4):687-695. doi: 10.3904/kjim.2019.196.
22. Morozova T.E., Vartanova O.A., Andreev S.S. Topical issues of choosing antihypertensive drugs. Consilium Medicum. 2016; 18(5):17-
23. Avdonina N.G., Korostovtsev L.S., Irtyuga O.B., Zvartau N.E., Konradi A.O. The choice of antihypertensive medicine in special groups of patients: age and gender distinctions. Arterial hypertension. 2014; 20(4):232-237.
24. Martsevich, S.Y., Zagrebelny A.V., Lukina Yu..V., et al. Analysis of the practice of using combination therapy with antihypertensive drugs according to the data of two outpatient registers. Russian cardiology journal. 2017; 22 (8):107-113.
25. ATC/DDD Index URL: https://www.whocc.no/atc_ddd_index/?code=C (Date of access 31.07.2019).